A recent study
has found that the SSRI antidepressant paroxetine—which is FDA-approved for the
treatment of hot flashes—may increase the risk of breast cancer.
approved Brisdelle as an opportunity to provide women with a non-hormonal
alternative to synthetic hormone replacement therapy for hot flashes, because
the latter can increase the risk of breast cancer. Women who suffer from hot
flashes are the most at-risk group for breast cancer.
Now that there
is evidence the new drug may promote breast cancer, the FDA should reverse its
irresponsible approval of Brisdelle—the trade name for this drug—immediately.
Please personalize your message, if you have the time!
Dear [Decision Maker],
Sincerely,[Your Name] [Your Address] [City, State ZIP]